Do cardiovascular risk factors modify the cardiotoxicity of lymphoma treatments?

Dean W Felsher

Prognostic Metabolic Signatures of Cancers Through Mass Spectrometry Imaging

Hodgkin lymphoma Non-Hodgkin lymphoma

Hematology and hematologic malignancies

Arash Ash Alizadeh

Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell Lymphoma

Non-Hodgkin lymphoma

Hematology and hematologic malignancies

Christopher S Carlson

Monitoring disease progression in follicular lymphoma with next-gen sequencing

Non-Hodgkin lymphoma

Pathology

Oliver W. Press

Therapy of Lymphoma/Leukemia with Monoclonal Antibodies

Hodgkin lymphoma Non-Hodgkin lymphoma

Manoj Menon

AMC PROTOCOL #075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma. A Trial of the AIDS Malignancy Consortium (AMC)

Hodgkin lymphoma

Hematology and hematologic malignancies

Stanley R. Riddell

Targeted therapy of B cell malignances with CAR-T cells of defined composition

Non-Hodgkin lymphoma

Franziska Michor

Evolution and Treatment Response of Brain, Breast, and Hematologic Malignancies

Hodgkin lymphoma Non-Hodgkin lymphoma

Martha Lassiter

2012 Tata Memorial Hospital Bone Marrow Transplant Program in Kolkata, India

Hodgkin lymphoma

Hematology and hematologic malignancies

Martha Lassiter

Duke University Nursing Oncology Training Exchange with Tata Memorial Hospital

Non-Hodgkin lymphoma Hodgkin lymphoma